Clinical Trial Update: Effect of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in People With Persistent Symptoms During the Subacute Period After Traumatic Brain Injury [Phase 2]

View source ↗

Summary

A Phase 2 trial examining the effect of recombinant erythropoietin on circulating endothelial progenitor cells in people with persistent symptoms after traumati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Traumatic Brain Injury

Drugs mentioned

• Recombinant erythropoietin (erythropoietin)

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Traumatic Brain Injury | Phase 2 | Status: WITHDRAWN